Neoantigen vaccines and cancer control: perspectives

Revista Colombiana de Cancerología

View Publication Info
 
 
Field Value
 
Title Neoantigen vaccines and cancer control: perspectives
Vacunas basadas en neoantígenos y control del cáncer: perspectivas
 
Creator Murillo Moreno, Raúl Hernando
 
Subject : Neoplasms
Neoantigens
Vaccines/terapeutic use
Cancer control
Neoplasias
Antígenos de neoplasias
Vacunas
Control cáncer
 
Description La supervivencia global y la calidad de vida son objetivos primarios del tratamiento del cáncer. El desarrollo de terapias blanco promovió el concepto de tratamientos personalizados, los que se han evaluado principalmente mediante desenlaces centrados en el tumor y han tenido foco en tumores de baja frecuencia y estados avanzados. La inmunoterapia rompe esta tendencia y genera expectativa por su efecto en la supervivencia global y su potencial uso en una gama amplia de tumores. Dentro de esta, las vacunas basadas en neoantígenos han mostrado alta eficacia y seguridad debido a su afinidad con células T y su elevada especificidad. Basado en sus principios biológicos se revisa su posible impacto en la carga de enfermedad según la relación entre potencial inmunogénico y prevalencia por tipo de tumor, el posible efecto en la práctica clínica por su combinación con otras modalidades de tratamiento, y el efecto en el acceso al tratamiento dado su proceso de desarrollo y producción y la disponibilidad de información propia.
 
Publisher Instituto Nacional de Cancerología
 
Date 2020-11-30
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
 
Identifier https://www.revistacancercol.org/index.php/cancer/article/view/195
10.35509/01239015.195
 
Source Revista Colombiana de Cancerología; Vol. 24 No. 4 (2020); 178-88
Revista Colombiana de Cancerología; Vol. 24 Núm. 4 (2020); 178-88
Revista Colombiana de Cancerología; v. 24 n. 4 (2020); 178-88
2346-0199
0123-9015
 
Language spa
 
Relation https://www.revistacancercol.org/index.php/cancer/article/view/195/525
/*ref*/Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-75. https://doi.org/10.1016/S0140-6736(17)33326-3 2. Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, et al. Assessment of the Evolution of Cancer Treatment Therapies. Cancers (Basel). 2011;3(3):3279-330. https://doi.org/10.3390/cancers3033279 3. Murillo R, Wiesner C, Acosta J, Piñeros M, Pérez JJ, Orozco M. Modelo para el cuidado del cáncer en Colombia. Bogotá: Serie Documentos Técnicos INC No. 5; 2015. 4. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 2000;100(1):57-70. https://doi.org/10.1016/S0092-8674(00)81683-9 5. Falzone L, Salomone S, Libra M. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Front Pharmacol. 2018;9:1300. https://doi.org/10.3389/fphar.2018.01300 6. World Health Organization. Pricing of Cancer Medicines and its Impacts. Geneva: WHO; 2018. 7. Albrecht B, Menu P, Tsao J, Webster K. The Next Wave of Innovation in Oncology. McKinsey Cancer Center. McKinsey&Company; 2016. 8. Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS. Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. Value Health. 2017;20(3):487-95. https://doi.org/10.1016/j.jval.2016.10.011 9. Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, et al. Perspectives in immunotherapy: meeting report from the immunotherapy bridge (29-30 November, 2017, Naples, Italy). J Immunother Cancer. 2018;6(1):69. https://doi.org/10.1186/s40425-018-0377-z 10. Hodi FS, O'Day, SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New Eng J Med. 2010;363(8):711-23. https://doi.org/10.1056/NEJMoa1003466 11. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123-35. https://doi.org/10.1056/NEJMoa1504627 12. Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei J, et al. Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol. 2019;12(1):93. https://doi.org/10.1186/s13045-019-0787-5 13. Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18(1):128. https://doi.org/10.1186/s12943-019-1055-6 14. Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168-82. https://doi.org/10.1038/nri.2017.131 15. Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, Zheng L, et al. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. J Immunol Res. 2018;2018:4325874. https://doi.org/10.1155/2018/4325874 16. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646-74. https://doi.org/10.1016/j.cell.2011.02.013 17. Bhatia A, Kumar Y. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. Expert Rev Clin Immunol. 2014;10(1):41-62. https://doi.org/10.1586/1744666X.2014.865519 18. Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10(459): eaat7807. https://doi.org/10.1126/scitranslmed.aat7807 19. Schumacher TN, Scheper W, Kvistborg P. Cancer Neoantigens. Annu Rev Immunol. 2019;37:173-200. https://doi.org/10.1146/annurev-immunol-042617-053402 20. Chu Y, Liu Q, Wei J, Liu B. Personalized cancer neoantigen vaccines come of age. Theranostics. 2018;8(15):4238-46. https://doi.org/10.7150/thno.24387 21. Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4:7. https://doi.org/10.1038/s41541-019-0103-y 22. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, et al. Personalized RNA Mutanome Vaccines Mobilize Poly-Specific Therapeutic Immunity Against Cancer. Nature. 2017;547(7662):222-6. https://doi.org/10.1038/nature23003 23. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217-21. https://doi.org/10.1038/nature22991 24. Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234-9. https://doi.org/10.1038/s41586-018-0792-9 25. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69-74. https://doi.org/10.1126/science.aaa4971 26. Castle JC, Uduman M, Pabla S, Stein RB, Buell JS. Mutation-Derived Neoantigens for Cancer Immunotherapy. Front Immunol. 2019;10:1856. https://doi.org/10.3389/fimmu.2019.01856 27. Aurisicchio L, Pallocca M, Ciliberto G, Palombo F. The perfect personalized cancer therapy: cancer vaccines against neoantigens. J Exp Clin Cancer Res. 2018;37(1):86. https://doi.org/10.1186/s13046-018-0751-1 28. Koşaloğlu-Yalçın Z, Lanka M, Frentzen A, Logandha Ramamoorthy Premlal A, Sidney J, Vaughan K, et al. Predicting T cell recognition of MHC class I restricted neoepitopes. Oncoimmunology. 2018;7(11):e1492508. https://doi.org/10.1080/2162402X.2018.1492508 29. Aldous AR, Dong JZ. Personalized neoantigen vaccines: a new approach to cancer immunotherapy. Bioorg Med Chem. 2018;26(10):2842-9. https://doi.org/10.1016/j.bmc.2017.10.021 30. Murillo R, Robles C. Research Needs for Implementing Cancer Prevention and Early Detection in Developing Countries: From Scientists' to Implementers' Perspectives. Biomed Res Int. 2019;2019:9607803. https://doi.org/10.1155/2019/9607803 31. World Health Organization. Global Report on Cancer. Geneva: WHO; 2020; in press. 32. Nature Editorial. A call for pragmatism in cancer research. Nat Rev Clin Oncol. 2018;15(4):193. https://doi.org/10.1038/nrclinonc.2018.41 33. Srivastava S, Koay EJ, Borowsky AD, De Marzo AM, Ghosh S, Wagner PD, et al. Cancer overdiagnosis: a biological challenge and clinical dilemma. Nat Rev Cancer. 2019;19(6):349-58. https://doi.org/10.1038/s41568-019-0142-8 34. Chen YP, Zhang Y, Lv JW, Li YQ, Wang YQ, He QM, et al. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. Theranostics. 2017;7(14):3585-94. https://doi.org/10.7150/thno.21471 35. International Agency for Research on Cancer/World Health Organization. Global Cancer Observatory [Internet]. Lyon: IARC; 2018. [Consultado el 15 de enero de 2020]. Disponible en: http://gco.iarc.fr 36. Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K, et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016;6(12):1382-99. https://doi.org/10.1158/2159-8290.CD-16-0577 37. O'Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL. The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. Clin Cancer Res. 2019;25(19):5743-51. https://doi.org/10.1158/1078-0432.CCR-18-2641 38. Moscow JA, Fojo T, Schilsky RL. The evidence framework for precision cancer medicine. Nat Rev Clin Oncol. 2018;15(3):183-92. https://doi.org/10.1038/nrclinonc.2017.186
 
Rights Derechos de autor 2020 Revista Colombiana de Cancerología
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library